Senkyunolide A

Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618) -induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis[1][2][3][4][5].

Product Specifications

CAS Number

[63038-10-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

α-synuclein

Type

Natural Products

Related Pathways

Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/senkyunolide-a.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1O[C@@H](CCCC)C2=C1C=CCC2

Molecular Formula

C12H16O2

Molecular Weight

192.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Kan WL, et al. Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol. 2008 Oct 30;120 (1) :36-43.|[2]Lei W, et al. Phthalides, senkyunolide A and ligustilide, show immunomodulatory effect in improving atherosclerosis, through inhibiting AP-1 and NF-κB expression. Biomed Pharmacother. 2019 Sep;117:109074.|[3]Gong S, et al. Senkyunolide A protects neural cells against corticosterone-induced apoptosis by modulating protein phosphatase 2A and α-synuclein signaling. Drug Des Devel Ther. 2018 Jun 25;12:1865-1879.|[4]Shao M, et al. Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. Pharm Biol. 2022 Dec;60 (1) :535-542.|[5]Yan R, et al. Low oral bioavailability and pharmacokinetics of senkyunolide a, a major bioactive component in Rhizoma Chuanxiong, in the rat. Ther Drug Monit. 2007 Feb;29 (1) :49-56.